Search research articles
Contact Us
Filters
Showing results (1-10 of 155) with videos related to
Page
of 16
Sort By:
JAMA Oncology
|
June 26, 2025
Tumor-Infiltrating Lymphocytes-An Area of Standardization-Reply
Maria Vittoria Dieci, Valentina Guarneri
The Lancet. Oncology
|
July 12, 2021
HER2: a never ending story
Maria Vittoria Dieci, Federica Miglietta
Expert Review of Anticancer Therapy
|
August 15, 2023
How can we refine the prognostic stratification of triple-negative breast cancer?
Federica Miglietta, Maria Vittoria Dieci
Expert Review of Anticancer Therapy
|
October 6, 2020
Should triple-positive breast cancer be recognized as a distinct subtype?
Maria Vittoria Dieci, Valentina Guarneri
Nature Reviews. Clinical Oncology
|
May 22, 2024
Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain
Maria Vittoria Dieci, Valentina Guarneri
The Lancet. Digital Health
|
December 11, 2025
Artificial intelligence and tumour-infiltrating lymphocytes in breast cancer: bridging innovation and feasibility towards clinical utility
Federica Miglietta, Maria Vittoria Dieci
Cancers
|
April 30, 2021
Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?
Cinzia Solinas, Debora Fumagalli, Maria Vittoria Dieci
Drugs
|
July 12, 2013
Relapsed triple-negative breast cancer: challenges and treatment strategies
Valentina Guarneri, Maria Vittoria Dieci, Pierfranco Conte
Expert Opinion on Pharmacotherapy
|
January 24, 2012
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer
Valentina Guarneri, Maria Vittoria Dieci, Pierfranco Conte
Cells
|
January 27, 2021
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
Maria Vittoria Dieci, Federica Miglietta, Valentina Guarneri
Page
of 16
Search research articles
Search
Showing results (1-10 of 155) with videos related to
Sort By:
Page
of 16
JAMA Oncology
|
June 26, 2025
Tumor-Infiltrating Lymphocytes-An Area of Standardization-Reply
Maria Vittoria Dieci, Valentina Guarneri
The Lancet. Oncology
|
July 12, 2021
HER2: a never ending story
Maria Vittoria Dieci, Federica Miglietta
Expert Review of Anticancer Therapy
|
August 15, 2023
How can we refine the prognostic stratification of triple-negative breast cancer?
Federica Miglietta, Maria Vittoria Dieci
Expert Review of Anticancer Therapy
|
October 6, 2020
Should triple-positive breast cancer be recognized as a distinct subtype?
Maria Vittoria Dieci, Valentina Guarneri
Nature Reviews. Clinical Oncology
|
May 22, 2024
Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain
Maria Vittoria Dieci, Valentina Guarneri
The Lancet. Digital Health
|
December 11, 2025
Artificial intelligence and tumour-infiltrating lymphocytes in breast cancer: bridging innovation and feasibility towards clinical utility
Federica Miglietta, Maria Vittoria Dieci
Cancers
|
April 30, 2021
Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting?
Cinzia Solinas, Debora Fumagalli, Maria Vittoria Dieci
Drugs
|
July 12, 2013
Relapsed triple-negative breast cancer: challenges and treatment strategies
Valentina Guarneri, Maria Vittoria Dieci, Pierfranco Conte
Expert Opinion on Pharmacotherapy
|
January 24, 2012
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer
Valentina Guarneri, Maria Vittoria Dieci, Pierfranco Conte
Cells
|
January 27, 2021
Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
Maria Vittoria Dieci, Federica Miglietta, Valentina Guarneri
Page
of 16